Vagus Nerve Stimulators Market by Product Type (Implantable Devices, and External Devices), by Application (Epilepsy, Depression, Cluster Headache & Migraine, and Others), by Distribution Channel (Hospital, Specialty Pharmacy, and Others), by Distribution

Vagus Nerve Stimulators Market by Product Type (Implantable Devices, and External Devices), by Application (Epilepsy, Depression, Cluster Headache & Migraine, and Others), by Distribution Channel (Hospital, Specialty Pharmacy, and Others), by Distribution Channel (Hospital, Retail Pharmacy, and Online Pharmacy) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Vagus nerve stimulation (VNS) refers to a technique which involves stimulating the vagus nerve including electrical or manual stimulation. Right cervical VNS is effective for treatment of heart failure, while the left cervical VNS is an effective treatment for refractory epilepsy as well as resistant depression. Vagus nerve stimulation can be performed through the use of vagus nerve stimulators, which send mild, regular pulses of electrical energy to the brain via the vagus nerve. Vagus nerve stimulators can either be implanted or used as an external handheld device. Traditionally, a vagus nerve stimulator is surgically implanted under the skin on the chest, while a wire is threaded under the skin which connects the device to the left vagus nerve. Some of the side effects associated with use of vagus nerve stimulators include changes in voice/speech, throat or neck pain, headache, insomnia, indigestion, nausea or vomiting, impaired sense of touch, and others.
Market Dynamics
The increasing prevalence of neurological disorders such as depression, anxiety, epilepsy, migraine, and others, rising technological advancements in vagus nerve stimulators, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global vagus nerve stimulators market over the forecast period.
For instance, according to an article published by the Neuroepidemiology journal, a peer-reviewed scientific journal, in 2020, it is estimated that the incidence of epilepsy was 61.4 per 100,000 person-years in 2017 with higher incidence in low/middle-income countries (139.0 per 100,000 person-years) than in high-income countries (48.9 per 100,000 person-years).
Key features of the study:
This report provides an in-depth analysis of the global vagus nerve stimulators market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global vagus nerve stimulators market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include LivaNova PLC, electroCore, Inc., SetPoint Medical Corporation, Beijing PINS Medical Co., Ltd., Parasym Ltd., Nervana, LLC, tVNS Technologies GmbH, BioControl Medical, NeurAxis, Inc., Soterix Medical Inc., MicroTransponder Inc., Boston Scientific Corporation, Cyberonics, Inc., EnteroMedics Inc., ReShape Lifesciences Inc., and Cerbomed GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global vagus nerve stimulators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vagus nerve stimulators market
Detailed Segmentation:
Global Vagus Nerve Stimulators Market, By Product Type:
Implantable Devices
External Devices
Global Vagus Nerve Stimulators Market, By Application:
Epilepsy
Depression & Anxiety
Cluster Headache & Migraine
Others (Crohn's disease, Dyskinesia, among others)
Global Vagus Nerve Stimulators Market, By End User:
Hospitals
Specialty Clinics
Others (Research Institutions, Ambulatory Surgical Centers, among others)
Global Vagus Nerve Stimulators Market, By Region:
North America
By Country
U.S.
Canada
Latin America
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Country
GCC
Israel
Rest of Middle East
Africa
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
LivaNova PLC*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
electroCore, Inc.
SetPoint Medical Corporation
Beijing PINS Medical Co., Ltd.
Parasym Ltd.
Nervana, LLC
tVNS Technologies GmbH
BioControl Medical
NeurAxis, Inc.
Soterix Medical Inc.
MicroTransponder Inc.
Boston Scientific Corporation
Cyberonics, Inc.
EnteroMedics Inc.
ReShape Lifesciences Inc.
Cerbomed GmbH
“*” marked represents similar segmentation in other categories in the respective section.